Brief: Qurient Therapeutics Enters Crada With The National Cancer Institute To Collaborate On A Phase 1/2 Clinical Study Of Q901 In Combination With Trop2-Adc
21/05/2024 14:30
May 21 (Reuters) - Qurient Co Ltd 115180.KQ :
* QURIENT THERAPEUTICS ENTERS CRADA WITH THE NATIONAL CANCER
INSTITUTE TO COLLABORATE ON A PHASE 1/2 CLINICAL STUDY OF Q901
IN COMBINATION WITH TROP2-ADC
Source text for Eikon: ID:nBw4hJ4WFa
Further company coverage: 115180.KQ
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Qurient
See all newsBrief: Lonza Expands Dual-Payload ADC Technology Offering Through Access To Qurient's CDK7 Inhibitors
Brief: Qurient To Conduct Capital Increase Of 8 Billion Won For Operational Funds
Brief: Qurient Therapeutics Enters Crada With The National Cancer Institute To Collaborate On A Phase 1/2 Clinical Study Of Q901 In Combination With Trop2-Adc
Brief: Qurient Announces Dosing Of First Patient In Q901 Phase 1/2 Clinical Study For The Treatment Of Patients With Solid Tumors
Brief: Qurient Announces Collaboration Agreement With MSD